A potential vaccine to prevent the spreading coronavirus could move into early-stage human testing in the next three months, the NIH’s infectious disease chief said.
Researchers may have a leg up on a new vaccine because the virus is part of a family that also includes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). That experience is speeding up the response, but getting a vaccine across the finish line to U.S. Food and Drug Administration approval will still take time.
“The bad news is that it happened. The good news is that we have considerable experience with ...